Bristol Myers Squibb (BMY) ended the recent trading session at $48.02, demonstrating a +2.85% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest and most well-known American pharmaceutical companies.

Bristol Myers Squibb is making progress paying down debt from prior deals and improving financial flexibility so it can make ...

The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 ...

To get a sense of who is truly in control of Bristol-Myers Squibb Company (NYSE:BMY), it is important to understand the ...

Bristol Myers Squibb said on Friday its blockbuster drug Reblozyl in combination with another therapy failed to meet the main ...

Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] ...

Pharmaceutical giants introduce an insurance-free pathway for top anticoagulant Eliquis, following similar direct-to-patient ...

This was the stock's second consecutive day of losses.

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who ...